Oncolytics Biotech INC

Oncolytics Biotech Inc. received a notification from Nasdaq for failing to meet the minimum $1.00 bid price requirement, with 180 days to regain compliance.

Oncolytics Biotech's pelareorep in combination with a checkpoint inhibitor has received FDA Fast Track designation for advanced anal cancer, targeting a significant unmet need.

Oncolytics Biotech announces FDA Type D meeting to discuss registrational pathway for REO 033 study in RAS-mutant colorectal cancer, with Part B designed for accelerated approval.

Oncolytics Biotech Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP due to corporate restructuring.

Oncolytics Biotech announced a new U.S. patent protecting its pelareorep manufacturing process until 2044, bolstering its intellectual property portfolio.

Oncolytics Biotech Inc. announced the appointment of John McAdory as Chief Operating Officer and Stephen Glover as a new Director to its Board.

Oncolytics Biotech reported a net loss of $9.24 million for Q1 2026, with significant increases in R&D and G&A expenses, while cash reserves remain a concern for long-term operations.

Oncolytics Biotech Inc. reports the grant of stock options to Director Angela Holtham, with vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Director James T. Parsons, with vesting over three years.

Oncolytics Biotech reports the Chief Financial Officer, Kirk Look, was granted 260,000 stock options with an exercise price of $1.06, vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Chief Business Officer Andrew Aromando, with vesting over three years.

Jared Kelly, CEO of Oncolytics Biotech, received stock options for 755,000 shares with an exercise price of $1.06, vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Chief Technology Officer Allison Hagerman, with specific vesting conditions and an exercise price tied to the stock's closing price on the grant date.

Anson Funds Management LP and affiliated entities have disclosed a 7% beneficial ownership stake in Oncolytics Biotech, Inc. through a Schedule 13G amendment.

Anson Funds Management LP and its affiliates have reported a passive beneficial ownership of 9.6% in Oncolytics Biotech, Inc., totaling 8,185,743 shares.